CytoAgents
PrivateLast Round
Grant
Oct 1, 2025
Est. Valuation
$52M
Total Funding Raised
$15.3M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
CytoAgents is a biotechnology company that develops innovative pharmaceutical products for the treatment of life-threatening symptoms associated with Cytokine Release Syndrome (CRS).
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
CytoAgents Comparables
Compare CytoAgents with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Poolbeg Pharma plc | 88% | |
| Taran Therapeutics, Inc. | 73% | |
| Incyte Corporation | 70% | |
CytoAgents Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Oct 1, 2025 | ||||
| Grant | Sep 25, 2024 | ||||
| Series A | May 11, 2023 | ||||
| Grant | Oct 3, 2021 | ||||
| VC Round | Aug 10, 2021 | ||||
Accelerator | Apr 5, 2021 |
CytoAgents Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| AlphaLab Health | Accelerator |
| Pittsburgh Life Sciences Greenhouse | Seed |
| National Cancer Institute | Grant |
| National Institute of Allergy and Infectious Diseases | Grant, Accelerator |
| NIH RADx | Grant, Accelerator |
| AHN | Accelerator |
| Richard King Mellon Foundation | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 18, 2026
Monthly visitors increased 77% MoM.
- Apr 18, 2026
Monthly visitors increased 541% MoM, reaching 2.3K.
CytoAgents Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about CytoAgents's valuation, stock price, and market status.